GA29144: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study To Evaluate The Efficacy And Safety Of Etrolizumab As An Induction And Maintenance Treatment For Patients With Moderately To Severely Active Crohn s Disease

Brief description of study

The purpose of this study is to determine whether etrolizumab is safe and to see how well it works in treating patients with moderately to severely active Crohn’s disease. Etrolizumab is an experimental drug, which means it has not been approved by the U.S. Food and Drug Administration (FDA) or other health authorities for the treatment of Crohn’s disease. Etrolizumab is designed to reduce the inflammation in the gastrointestinal tract (stomach and intestines) that occurs with Crohn’s disease.

Clinical Study Identifier: s15-00576 Identifier: NCT02394028
Principal Investigator: Robert E Tepper.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.